News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Phase III
Radius (RDUS) Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 12/22/2014
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014
Receptos (RCPT) Initiates SUNBEAM Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis 12/22/2014
TiGenix Submits Its Pivotal US Trial Design For Cx601 To FDA For Special Protocol Assessment 12/22/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/19/2014
ImmunoGen, Inc. (IMGN) Reports Roche (RHHBY) Has Provided An Update On The MARIANNE Trial 12/19/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
TetraPhase Pharmaceuticals (TTPH) Surges As Antibiotic Succeeds In Late-Stage Trial 12/18/2014
Pfizer (PFE) Shows Off Significant Data From Pregabalin CR Phase 3 12/18/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/18/2014
SoCal's Auspex Pharmaceuticals (ASPX) Soars 90% On Huntington's Disease Drug Trial Data 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
Pfizer (PFE) Reports Top-Line Results From A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As A Treatment For Patients With Postherpetic Neuralgia 12/18/2014
TetraPhase Pharmaceuticals (TTPH) Announces Positive Top-Line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-Abdominal Infections 12/18/2014
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Extab Corporation Announces Positive Data From Phase 3 Clinical Study Of Cytisine As A Smoking Cessation Aid Published In The New England Journal Of Medicine 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
Sophiris Bio Inc. (SPHS) Tanks As Phase 3 Data Indicates Drug May Not Be Effective 12/16/2014
Celldex Therapeutics, Inc. (CLDX) Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma 12/16/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis 12/16/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 12/15/2014
Sophiris Bio Inc. (SPHS) Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 12/15/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits 12/15/2014
Novartis AG (NVS) Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Late-Stage Study 12/12/2014
Nektar Therapeutics (CA) (NKTR) Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer 12/12/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Alnylam Pharmaceuticals (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-Ttrsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis 12/12/2014
Janssen Research & Development Release: Data From The EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented At San Antonio Breast Cancer Symposium 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014
Phase 3 Results From German Breast Group (GBG) Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel (Abraxane®) Vs. Solvent-Based Paclitaxel 12/11/2014
Macrocure (MCUR) Announces Completion Of Mechanism Of Action Study 12/11/2014
Galena Biopharma  (GALE) Presents HER2 Screening Data Including Preliminary Leica Bond Oracle™ Results From the Phase 3 NeuVax™ (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) 12/11/2014
EXCLUSIVE: AbbVie (ABBV) VP Says New Cancer Drug Could Treat Other Diseases 12/11/2014
Eli Lilly (LLY), Incyte Corporation (INCY) Arthritis Drug Meets Endpoint In Phase 3 12/10/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY) ADCETRIS Phase 3 Demonstrated Statistically Significant Improvement In Progression-Free Survival 12/10/2014
Bavarian Nordic (BAVA.CO) Reaches Enrollment Target In The Pivotal Phase 3 Study Of PROSTVAC® In Prostate Cancer 12/10/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson’s Disease 12/10/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014
Bristol-Myers Squibb Company (BMY) Release: Anticoagulant Effect Of Eliquis (Apixaban) Reversed By Two Separate 4-Factor Prothrombin Complex Concentrates In Healthy Subjects 12/9/2014
New Data At American Society of Hematology 2014 Highlight Progress Of Pfizer (PFE)’s Growing Portfolio In Blood Cancers 12/9/2014
Celgene (CELG) Release: Data Presented On REVLIMID® (lenalidomide) Compared With Investigators’ Choice In Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/9/2014
Celgene (CELG) Release: Results From Phase 3 Study Of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence In Patients With Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented At American Society of Hematology 12/9/2014
Novartis AG (NVS) Release: Six-Year Pivotal Study Data Reinforce The Superiority Of Tasigna Over Gleevec In Newly-Diagnosed Patients With Ph+ CML 12/9/2014
New Trial Initiated Evaluating Amgen (AMGN)'s Talimogene Laherparepvec In Combination With Merck & Co. (MRK)'s Anti-PD-1 Therapy KEYTRUDA (Pembrolizumab) For Advanced Melanoma 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival In Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation 12/9/2014
CTI BioPharma Announces Presentation Of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance In FLT3-ITD Positive AML Cells 12/9/2014
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study Of Lead Antiviral FV-100 For Treating Shingles 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Celgene (CELG) Release: Results From Phase 3b Study Of POMALYST®/IMNOVID® (Pomalidomide) Plus Low-Dose Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma Presented At American Society of Hematology 12/9/2014
Celgene (CELG) Release: Additional Analyses Of High-Risk Patients From Phase 3 Study (AML-001) OF Vidaza® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At American Society of Hematology 12/9/2014
SSF's Sunesis Pharmaceuticals, Inc. (SNSS) Believes It Can End 40 Year AML Drought Despite "Failed" Phase 3 Study 12/8/2014
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen (AMGN)'s NEUPOGEN® 12/8/2014
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Results From Phase 3 VALOR Trial At American Society of Hematology Annual Meeting 12/8/2014
CTI BioPharma Announces Comprehensive Kinome Analysis That Demonstrates Pacritinib Inhibits Kinases Linked To A Spectrum Of Blood-Related Cancers 12/8/2014
Novo Nordisk A/S (NVO) Release: Novoeight Phase 3 Data Show Reduction In Annualised Bleeding Rate Over Time In People With Haemophilia A 12/8/2014
American Society of Hematology Release: Novel Combinations Of New And Existing Therapies Yield Promising Results for Leukemia Patients With Poor Prognoses 12/8/2014
Vital Therapies, Inc. (VTI) (VTL) Announces First Subject Enrolled In VTI-210 And Provides Update On Enrollment In VTI-208 12/8/2014
BioDelivery Sciences International (BDSI) Announces Completion Of Randomization In Phase 3 Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy 12/8/2014
Upsher-Smith Laboratories Presents New Data From Year-Long, Open-Label Extension Study Of Qudexy XR (Topiramate) Extended-Release Capsules At 68th Annual American Epilepsy Society Meeting 12/8/2014
Orexo Features Positive Results From The ISTART Study At The 2014 AAAP Meeting 12/8/2014
ACADIA Pharmaceuticals, Inc. (ACAD) Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson’s Disease And Related Disorders 12/8/2014
CEL-SCI (CVM) Expands Its Pivotal Phase 3 Immunotherapy Head And Neck Cancer Trial With Addition Of 7 More Clinical Sites 12/8/2014
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Report Phase 3 AETHERA Clinical Trial Data From ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At Risk Of Relapse At American Society of Hematology Annual Meeting 12/8/2014
ERYtech Pharma Reports Additional Positive Phase 3 Results From Clinical Study With ERY-ASP/GRASPA® In Acute Lymphoblastic Leukemia 12/8/2014
Celgene (CELG) Release: Age, Renal Impairment and Depth of Response Analyses of the First™ (MM-020/IFM 07-01) Study of Continuous REVLIMID® (Lenalidomide) Plus Low-Dose Dexamethasone In Newly-Diagnosed Multiple Myeloma Presented at American Society of Hematology 12/8/2014
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014
PaxVax, Inc. Announces Primary Endpoints Met In Phase 3 Cholera Vaccine Trial 12/8/2014
Novartis AG (NVS) Copy Of Amgen (AMGN) Cancer Drug Shows Similar Efficacy 12/8/2014
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014
FDA Grants Breakthrough Therapy Status To Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Ixazomib 12/8/2014
Intercept Pharmaceuticals (ICPT) Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology 12/5/2014
CytRx Corporation (CYTR) Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials 12/4/2014
Investors Cheer As Biogen Idec (BIIB)'s BIIB037 Skips To Phase 3 For Alzheimer's 12/4/2014
Phase 3 Results Published In The New England Journal of Medicine Show Superiority Of Pfizer (PFE)’s XALKORI® (crizotinib) Compared To Platinum-Based Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer 12/4/2014
ADMA Biologics, Inc.'s Primary Endpoint Achieved, Touts Positive Phase 3 Data 12/3/2014
Novartis AG (NVS) Flu Vaccine FLUAD Suspended Following 13 Reported Deaths 12/3/2014
Novartis AG (NVS) Fingolimod Ph3 Trial In PPMS Fails To Meet Primary Goal 12/3/2014
Prothena Corporation plc Targets Rare Protein-Misfolding Disease In Late-Stage Study 12/3/2014
First MS Patients In The U.S. Receive Genzyme Corporation (GENZ)’s Lemtrada Following FDA Approval 12/3/2014
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Trial Of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 12/3/2014
Prothena Corporation plc Initiates NEOD001 Global Phase 3 Registrational Trial Based On Positive Results In Ongoing Phase 1/2 Study Of NEOD001 In Patients With AL Amyloidosis 12/3/2014
BeyondSpring Pharmaceuticals To Conduct Phase 3 Trial Of Lead Candidate Plinabulin In NSCLC 12/3/2014
Exelixis, Inc. (EXEL) COMET-2 Ph3 Cabozantinib Trial Fails To Meet Primary Endpoint 12/2/2014
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 12/2/2014
CEL-SCI (CVM) Quarterly Patient Enrollment In Its Head And Neck Cancer Phase 3 Trial Increases Eight Fold Over Same Prior Year Period 12/2/2014
Exelixis, Inc. (EXEL) Announces Results From The COMET-2 Pivotal Phase 3 Trial Of Cabozantinib In Men With Metastatic Castration-Resistant Prostate Cancer 12/1/2014
Mylan Inc. (MYL), Gilead Sciences, Inc. (GILD) Ink Agreement Covering Non-Exclusive TAF Rights 12/1/2014
Celator Pharmaceuticals, Inc. Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351 12/1/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback From European Medicines Agency On Advancing ICT-107 To Phase 3 Program 12/1/2014
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Zogenix, Inc. (ZGNX) Release: Results Of Long-Term, Open-Label Study Published In The Journal Of Pain Research Demonstrate The Safety, Tolerability And Effectiveness Of Zohydro ER 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
FDA Requires Additional Data On Bristol-Myers Squibb Company (BMY)' Hep C Daclatasvir 11/26/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study Met All Primary Endpoints Against Johnson & Johnson (JNJ)'s Stelara 11/26/2014
Amgen (AMGN) Terminates All Rilotumumab Clinical Trials For Advanced Gastric Cancer 11/26/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Children With Spinal Muscular Atrophy 11/25/2014
R-Tech Ueno Received Orphan Drug Designation For Unoprostone Isopropyl (Development Code:UF-021) For The Treatment Of Retinitis Pigmentosa From MHLW 11/25/2014
Intra-Cellular Therapies, Inc. Announces Enrollment Of First Patient In Phase 3 Trial Of ITI-007 For The Treatment Of Schizophrenia 11/25/2014
Ferring Pharmaceuticals Release: New Data From A Pooled Analysis Shows Improved Overall Survival For Prostate Cancer Patients Treated With FIRMAGON® (Degarelix) Compared To LHRH Agonists 11/25/2014
Onxeo Announces Positive DSMB Recommendation For Its Phase 3 Trial With Livatag® In Primary Liver Cancer 11/24/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of REVEAL-1 Trial Results In The British Journal Of Haematology 11/24/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/24/2014
Top 10 Countries For Diabetes Clinical Research 11/21/2014
Relypsa, Inc. (RLYP) Announces Data Published In The New England Journal of Medicine For Pivotal Phase 3 Program Of Patiromer FOS For The Treatment Of Hyperkalemia 11/21/2014
ZS Pharma (ZSPH) Announces Publication Of Results From Phase 3 Study Of ZS-9 In Patients With Hyperkalemia In The New England Journal of Medicine 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. (4568.t) Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108 11/20/2014
TrovaGene, Inc. Releases Clinical Study Results For The Detection And Monitoring Of KRAS Mutations In Circulating Tumor DNA Of Colorectal Cancer Patients 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Titan Pharmaceuticals (TTP) Announces Completion Of Enrollment In Phase 3 Study Of Probuphine For Opioid Dependence 11/20/2014
Merrimack Pharmaceuticals Inc. (MACK) Receives FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer 11/19/2014
FDA Puts Partial Hold On CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Trials 11/19/2014
SOTIO Initiates US Part Of VIABLE, A Global Phase III Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
Genzyme Corporation (GENZ) And Isis Pharmaceuticals, Inc. (ISIS) Present KYNAMRO® Clinical Data At American Heart Association 11/19/2014
ZS Pharma (ZSPH) Presents Positive Results From HARMONIZE (ZS004), A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia, At The American Heart Association Scientific Meeting And Announces Simultaneous Publication Of Results In JAMA 11/17/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Novartis Pharmaceutical Corporation (NVS) AIN457 (secukinumab) Showed Significant Symptom Improvement In Two Pivotal Phase 3 ankylosing spondylitis Studies 11/17/2014
TissueGene, Inc. Receives Recommendations From FDA On Pathway To Phase 3 Trial Of TG-C For Treatment Of Osteoarthritis Of The Knee 11/17/2014
Keryx Biopharmaceuticals (KERX) Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 11/17/2014
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac And Composite Endpoints From Fabry Monotherapy Study 012 At American Society of Nephrology 11/17/2014
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Statistically Significant Results From The First Part Of The Phase 3 ANNEXA(TM)-A Studies Of Investigational Andexanet Alfa With Eliquis (Apixaban) 11/17/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Late-Breaking Presentation Of Phase 3 VALOR Trial At American Society of Hematology Annual Meeting 11/17/2014
Bristol-Myers Squibb Company (BMY) Release: Study Comparing Opdivo (Nivolumab) To Chemotherapy In Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor To Demonstrate A Survival Benefit In A Phase 3 Trial 11/17/2014
Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data At American Academy Of Physical Medicine And Rehabilitation Annual Assembly 11/17/2014
Bristol-Myers Squibb Company (BMY) Release: Analyses From Phase 3b Study Provide Additional Data In Earlier Use Of Orencia (Abatacept) Plus Methotrexate (MTX) In Citrullinated Protein (CCP)-Positive Adult Patients With Early Rheumatoid Arthritis (RA) 11/17/2014
Nine New Analyses Show Novartis Pharmaceuticals Corporation (NVS)' LCZ696 Could Change Course Of Heart Failure For Patients 11/17/2014
Eli Lilly (LLY) Release: New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight And Markers Of Abdominal Fat In Adults With Type 2 Diabetes 11/17/2014
Iroko Pharmaceuticals Release: New Long-Term Safety And Quality Of Life Data Reported For ZORVOLEX® In Osteoarthritis Patients 11/17/2014
AstraZeneca PLC (AZN) Presents Data From Phase 3 Studies Of Lesinurad In Combination With Allopurinol In Gout Patients At American College of Rheumatology 2014 Annual Meeting 11/17/2014
NovoCure Ltd. Announces The EF-14 Phase 3 Clinical Trial Of Tumor Treating Fields In Patients With Newly Diagnosed Glioblastoma Has Been Terminated At The Interim Analysis Due To Early Success 11/17/2014
Provectus Biopharmaceuticals Inc.’ Protocol For Phase 3 Study Of PV-10 As Treatment For Melanoma Now Available Online 11/13/2014
Amgen (AMGN) And AstraZeneca PLC (AZN) Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 11/12/2014
Amgen (AMGN) And AstraZeneca PLC (AZN)'s Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Phase 3 Study 11/12/2014
Animal Study Confirms Results Of ChromaDex, Inc. Human Clinical Study On Weight Loss With Pterostilbene 11/12/2014
TiGenix Completes Patient Recruitment For The European Phase 3 Trial Of Cx601 Ahead Of Schedule 11/12/2014
SSF's Threshold Pharmaceuticals, Inc. (THLD) Snags Fast Track Status For Experimental Cancer Drug TH-302 11/11/2014
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014
Highland Therapeutics Announces Positive Top-Line Data From Phase 3 Trial 11/11/2014
Synageva BioPharma (GEVA) Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The American Association for Study of Liver Diseases Meeting 11/11/2014
BioCardia Announces FDA Acceptance Of Phase 3 Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy For Heart Failure Patients 11/11/2014
Threshold Pharmaceuticals, Inc. (THLD) Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma 11/11/2014
BioCardia Announces FDA Acceptance Of Phase 3 Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy For Heart Failure Patients 11/11/2014
FDA Grants QIDP Fast-Track Designation To RedHill Biopharma Ltd. (RDHL)'s Phase 3 H. Pylori Drug RHB-105 11/10/2014
Bristol-Myers Squibb Company (BMY) Release: Phase 3 UNITY Trials Demonstrate High Cure Rates For Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination In Genotype 1 Hepatitis C Patients, Including Those With Cirrhosis 11/10/2014
Bristol-Myers Squibb Company (BMY) Release: ALLY Trial Demonstrates High Cure Rates For Investigational Daclatasvir And Sofosbuvir Combination Among Genotype 3 Hepatitis C Patients 11/10/2014
Dynavax Technologies Corporation (DVAX) Announces Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B™ 11/10/2014
Amgen (AMGN) Highlights New Data In The Treatment Of Blood Cancers At American Society of Hematology 2014 11/7/2014
Provectus Biopharmaceuticals Inc. Submits PV-10 Phase 3 Melanoma Protocol To FDA 11/7/2014
Cardiome Pharma Corp. (COM.TO) Touts Positive Data From Phase 3 BRINAVESS® Trial 11/7/2014
Spark Therapeutics Snags FDA Breakthrough Therapy Designation For Lead Product 11/6/2014
Genmab A/S (GEN.CO) Announces Additional Data From Phase 3 Study Of Ofatumumab As Maintenance Therapy For Relapsed CLL 11/6/2014
ZS Pharma (ZSPH) Announces Late Breaking Presentation Of Phase 3 HARMONIZE (ZS004) Trial Results In Patients With Hyperkalemia At American Heart Association Annual Meeting 11/6/2014
Exelixis, Inc. (EXEL) Completes Enrollment Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Metastatic Renal Cell Carcinoma 11/6/2014
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Huntington's Disease 11/6/2014
Nine Out Of 10 Lost Weight With Novo Nordisk A/S (NVO)'s Obesity Drug Liraglutide 11/5/2014
Amgen (AMGN) Drug Fails To Increase Overall Survival In Ovarian Cancer Patients 11/5/2014
Celsion Corporation (CLSN) Receives VHP Approval To Initiate OPTIMA Study In Europe 11/5/2014
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers 11/5/2014
Ironwood Pharmaceuticals (IRWD) Initiates Phase 3 Trial Of 72 mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation 11/5/2014
The Medicines Company (MDCO) Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria 11/5/2014
Sanofi Pasteur (SASY.PA)'s Investigational Dengue Vaccine Hits Main Goal Showing Efficacy In Phase 3 Trial 11/4/2014
Novo Nordisk A/S (NVO) Release: New Phase 3a Data Demonstrate That 9 Out Of 10 Adults With Obesity Lost Weight With Liraglutide 3 Mg And Clinical Trial Completers Lost An Average Of 9.2% 11/4/2014
XOMA (US) LLC (XOMA) Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum 11/4/2014
Nymox Pharmaceutical (NYMX) Tanks As Lead Drug Fails To Meet Primary Endpoints In Two Large Studies 11/4/2014
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Completes Target Enrollment In The TH-302 Phase 3 MAESTRO Study In Patients With Locally Advanced Or Metastatic Pancreatic Adenocarcinoma 11/4/2014
Nymox Pharmaceutical (NYMX) NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 And NX02-0018 Fail To Meet Primary Efficacy Endpoints 11/3/2014
Nuvo Research Inc. (NRI.TO) Plans Phase 3 Study Of Pennsaid® 2% To Support International Regulatory Approvals 11/3/2014
CEL-SCI (CVM) Enrolls 22 Patients During October In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 11/3/2014
FDA Grants Orphan Drug Designation To Astellas Pharma Inc. (ALPMY) For Isavuconazole For The Treatment Of Invasive Candidiasis 11/3/2014
Antares Pharma, Inc. (ATRS) Announces Last Patient Enrolled In Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males 11/3/2014
ZS Pharma (ZSPH) Announces Multiple Presentations From ZS003, A Phase 3 Trial Of ZS-9, At The American Society of Nephrology Annual Meeting 10/31/2014
AVANIR Pharmaceuticals (AVNR) Announces Publication Of Pivotal Phase 3 Results From AVP-825 Acute Migraine Study In The Journal "Headache" 10/31/2014
Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) To Be PBS Listed For Metastatic Pancreatic Cancer 10/31/2014
CSL Behring Release: Evidence Presented At The 16th Biennial Meeting Of The European Society For Immunodeficiencies (ESID) Supports Individualized Dosing With Hizentra® 10/31/2014
Medivation, Inc. (MDVN) And Astellas Pharma US Announce Phase 3 Study Of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy 10/31/2014
Arena Pharmaceuticals, Inc. (ARNA) Skimps On Data Disclosure From Weight-Loss Combo Study: Analyst 10/30/2014
Versartis, Inc. (VSAR) Schedules Conference Call To Discuss Plans For Phase 3 Trial For VRS-317 In Pediatric Growth Hormone Deficiency Patients 10/30/2014
Helsinn Group Release: New Data On Fatigue From ROMANA 1, A Pivotal Phase III Study Of Anamorelin In Advanced NSCLC Patients With Cachexia Presented At 2014 Chicago Multidisciplinary Symposium In Thoracic Oncology 10/30/2014
Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial For SD-809 In Tardive Dyskinesia 10/30/2014
Neurocrine Biosciences, Inc. (NBIX) Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia 10/30/2014
Promising Data Presented At The Chicago Multidisciplinary Symposium On Thoracic Oncology From An Investigator-Sponsored Trial Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Pemetrexed And Carboplatin In Front-Line Non-Small Cell Lung Cancer 10/30/2014
The Medicines Company (MDCO) Announces Presentation Of Investigational Hemostatic Agent RAPLIXA™ (Fibrin Sealant) Phase 3 FINISH-3 Trial Results At The 2014 Clinical Conference Of American College of Surgeons 10/29/2014
Novartis AG (NVS) Expects New Heart Failure Drug As "Multi-Blockbuster" 10/29/2014
Adamas Pharmaceuticals (ADMS) Expands Its Phase 3 Program With ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Patients With Parkinson's Disease 10/29/2014
Lipid Therapeutics' European Partner Dr. Falk Pharma Gmbh Enrolls First Patients Into Pivotal Phase 3 Trial With LT-02, A Novel Therapy For Ulcerative Colitis (UC) 10/29/2014
New Clinical Trial Data: The Scripps Research Institute MS Drug Candidate Also Shows Promise For Ulcerative Colitis 10/28/2014